Laser interstitial thermal therapy in the management of bottom‐of‐sulcus dysplasia‐related epilepsy
Annals of Clinical and Translational Neurology · 2025-01 · 12 (1) · 110-120
DOI: 10.1002/acn3.52258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 03.12.2024. Verfasst von Bowen Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Laser Therapy, Epilepsy, Neurosurgical Procedures. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Beijing Nova Program.
Abstract (Originalsprache)
Objective
This study assessed the efficacy and safety of magnetic resonance‐guided laser interstitial thermal therapy (MRgLITT) versus open surgery (OS) for the treatment of patients with bottom‐of‐sulcus dysplasia (BOSD)‐related epilepsy.
Methods
Twenty‐two patients underwent MRgLITT, while 39 underwent OS. Postoperative seizure‐free rates were analyzed using Kaplan–Meier curves. The removal ratio, which represents the extent of damage, was calculated based on preoperative lesion volume and postoperative removal volume. Other outcomes, including adverse events, operative time, and hospital stay, were also compared.
Results
Kaplan–Meier curves indicated the seizure‐free rates were comparable between the MRgLITT group (90.9%, 26.5 [23.0, 35.1] months) and OS group (89.7%, 25.2 [16.2, 34.6] months) at the final follow‐up ( p = 0.901, log‐rank test). The removal ratio of MRgLITT (1.3 [1.1, 1.7]) was significantly lower ( p = 0.007) than that of OS (5.8 [3.6, 8.5]). A comparison of postoperative neurological deficits, infection rates, and fever rates revealed no significant differences between MRgLITT and OS groups. The operative time (hours) of MRgLITT (3.0, [2.1, 4.9]) was significantly shorter ( p = 0.007) than that of OS (3.5 [3.0, 4.5]). The hospital stay (days) after MRgLITT (6 [5.0, 7.5]) was significantly shorter ( p < 0.001) than that of OS (11.0 [9.0, 13.5]).
Interpretation
MRgLITT has advantages over OS, including comparable seizure control and adverse event profiles, along with reduced removal ratios, shorter operative time, and shorter hospital stays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Stereotactic and Functional Neurosurgery Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Bowen Yang, Baotian Zhao, Jiajie Mo, Xiaoqiu Shao, Jianguo Zhang, Kai Zhang
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Beijing Nova Program
- Beijing Municipal Science & Technology Commission
- Natural Science Foundation of Beijing Municipality
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Yang, B., Zhang, C., Wang, X., Zhao, B., Mo, J., Luo, W., Shao, X., Zhang, J., Zhang, K., & Hu, W. (2025). Laser interstitial thermal therapy in the management of bottom‐of‐sulcus dysplasia‐related epilepsy. Annals of Clinical and Translational Neurology, 12(1), 110-120. https://doi.org/10.1002/acn3.52258
Vancouver
Yang B, Zhang C, Wang X, Zhao B, Mo J, Luo W, et al. Laser interstitial thermal therapy in the management of bottom‐of‐sulcus dysplasia‐related epilepsy. Annals of Clinical and Translational Neurology. 2025;12(1):110-120. doi:10.1002/acn3.52258
BibTeX
@article{Yang2025,
author = {Yang, Bowen and Zhang, Chao and Wang, Xiu and Zhao, Baotian and Mo, Jiajie and Luo, Weiyuan and Shao, Xiaoqiu and Zhang, Jianguo and Zhang, Kai and Hu, Wenhan},
title = {Laser interstitial thermal therapy in the management of bottom‐of‐sulcus dysplasia‐related epilepsy},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
volume = {12},
number = {1},
pages = {110--120},
doi = {10.1002/acn3.52258}
}
EUVIMED